Navigation Links
Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
Date:2/26/2008


DUSSELDORF, Germany, February 26 /PRNewswire-FirstCall/ --

- Sales in 2007 Increased by 48.1% to EUR957.7m

- Operating Results (Adjusted EBITDA) up by 48.1% at EUR181.6m

- Proposed Dividend: EUR0.40 Per Share - CEO Dr. Axel Herberg: "For the Financial Year 2008 we Expect Further Sales Growth, With an Improved Margin."

Gerresheimer AG has finished the financial year 2007 with record figures in terms of sales and results. The company increased its sales by 48.1% to EUR957.7m (2006: EUR646.7m). Excluding acquisition and exchange-rate effects, Gerresheimer reports above-average sales growth of 8.4%. Operating results (Adjusted EBITDA) rose by 48.1% from EUR122.6m in the prior year to EUR181.6m. The company's operating strength is shown by the Adjusted EBITDA margin of 19.0%.

The debt level before the IPO and the one-off costs of the IPO are reflected in consolidated results of EUR0.8m (2006: EUR-25.0m). In the fourth quarter, however, consolidated results already totalled EUR13.9m, reaching a level which was no longer depressed by IPO costs and for the first time reflected the company's low level of debt. The adjusted consolidated results improved strongly during the financial year to EUR44.3m (2006: EUR8.7m).

"We have achieved all the targets we set ourselves for 2007 and in many cases exceeded them. For our company we look back over a very successful financial year", says Dr. Axel Herberg, CEO of Gerresheimer AG. Against the background of this brilliant business development, the Management Board and the Supervisory Board will propose to the Shareholders' Meeting that a dividend is already distributed for the financial year of the IPO, which is to amount to EUR0.40 per share.

Continuation of globalisation strategy

The strong growth of Gerresheimer AG is attributable on the one hand to above-average organic growth and on the other hand to acquisitions. The Wilden Group, which was acquired at the sta
'/>"/>

SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CIGNA Medical Group Selects Allscripts for Electronic Health Record
2. Eklin Medical Reports Record Revenues for 2007
3. Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients
4. GeoPharma Announces Record Revenues in Third Quarter Results
5. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
6. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
7. BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates
8. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
9. Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January
10. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
11. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... TorreyPines Therapeutics, Inc.,(Nasdaq: TPTX ) today announced that ... the U.S. Food and Drug Administration (FDA) on,September 29, ... data, the FDA agreed,that TorreyPines may initiate a Phase ... confirmed that the required thorough QT/QTc study,for tezampanel can ...
... 1 SpectraScience, Inc. (OTC,Bulletin Board: SCIE), a ... has shipped its non-invasive WavSTAT(R) Optical Biopsy,System to ... clinical,value of the Optical Biopsy System as an ... or cancer in the esophagus.,This marks the final ...
... Oct. 1 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... of anti-adhesion products and other surgical,implants, announced today ... a,private placement in which it received $4.0 million ... issuance to investors of ten million units,at $0.40 ...
Cached Biology Technology:TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 2TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 3TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 4University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 2University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 3University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia 4SyntheMed Completes $4.0 Million Equity Placement 2
(Date:7/31/2015)... 2015 La 10e Conférence internationale sur ... par le BGI du 22 au 25 octobre ... Chine. La conférence célèbre son 10e ... l,ICG est devenue l,une des réunions annuelles mondiales ... et c,est aussi la plus dynamique, la plus ...
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s touch ... 2015 that relate to sales of FPC1025 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... China and we are proud that ZTE ... Axon , its first smartphone ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... Up-to-date marine data enables students to carry out ... how scientific knowledge is created and developed, according to ... from the University of Gothenburg followed upper-secondary students from ... study was part of the research project I2I, Inquiry ...
... Rochelle, May 14, 2012 Disruptive Science and Technology ... Mary Ann Liebert, Inc., publishers, has officially released ... PhD, Highmark Distinguished Career Professor, Carnegie Mellon University, ... thorough syntheses and analyses focused on front-line concepts ...
... ST. LOUIS, MO, May 14, 2012Arranging DNA fragments into a ... compared to assembling a puzzle except you don,t have the ... to be. Sometimes clues from other publicly-available DNA sequences of ... but its usefulness depends on how closely related any two ...
Cached Biology News:Real science in virtual school labs 2New journal on disruptive science and technology launched by Mary Ann Liebert Inc. publishers 2Researchers look to relatives for clues in quest to develop sources of bioenergy 2Researchers look to relatives for clues in quest to develop sources of bioenergy 3
... 301 Power Supply, 1. 300 V, ... or constant current modes.Single-unit increments in ... reproducibility.Suitable for submarine, mini vertical, and ... as semidry and mini tank blotting ...
... Supply, 1. 1000 V, 400 mA, ... and constant power modes.Single-unit increments in ... reproducibility.Stores and recalls three protocols.Outstanding choice ... Multiphor II or GenePhor systems. ...
Mouse TrkC Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: